ClinicalTrials.gg
CompletedNCT07305779Updated Jan 15, 2026

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

A Phase 1 interventional study of SEP-380135 and Quinidine Gluconate in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.
  • Registered 9 months after the study started (first participant enrolled Mar 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..

Enrollment
105th of 111
12 · median 125
Started
2025
with 2 others
Phase 1
34 of 120
1 open now
Registered
118th of 120
by date

Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 105th largest by enrollment of the 111 interventional ones that give a count, is one of 3 that started in 2025, is one of 34 in phase 1, and was the 118th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Mental Health Conditions
  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants between 18 and 55 years of age (inclusive) at time of consent
  2. from 18.0 to 32.0 kilograms per square meter (kg/m\^2) (inclusive).
  3. In good health as determined by:

    1. Medical history
    2. Physical examination
    3. Vital signs
    4. Neurological examination
    5. Serum chemistry, lipid panel, thyroid panel, coagulation panel, urinalysis, hematology, and serology tests (from screening visit).
  4. Willing to stay in the clinic for the required period (i.e., to be hospitalized for 10 days) and willing to be contacted for the safety follow-up telephone call.
  5. Ability to provide written, prior to initiation of any trial-related procedures, and ability, in the opinion of the Principal Investigator, to comply with all the requirements of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Have taken an drug within 30 days or 5 half-lives, if known, (whichever is longer) prior to screening.
  2. Have had previous exposure to SEP-380135.
  3. Are currently participating in another clinical trial.
  4. Attempted suicide within 12 months prior to screening.
  5. A history of sick sinus syndrome, first-, second-, or third-degree atrioventricular block, myocardial infarction, Class II-IV heart failure, cardiomyopathy, pulmonary congestion, cardiac arrhythmia, prolonged , congenital long QT syndrome, family history of long QT, or moderate to severe hypokalemia. A participant with non- abnormalities at screening and check-in requires approval from the medical monitor and the sponsor's physician.
  6. In the opinion of the investigator, should not participate in the trial.

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    SEP-380135 + Quinidine Gluconate

    Participants receive SEP-380135 alone on Day 1, followed by administration of quinidine gluconate beginning on Day 6. On Day 7, SEP-380135 is coadministered with quinidine gluconate. Quinidine gluconate dosing continues from Day 8 to Day 10.

    Drug: SEP-380135 · Drug: Quinidine Gluconate

Interventions

  • DrugSEP-380135

    Oral capsules.

  • DrugQuinidine Gluconate

    Oral extended-release (ER) tablets.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of SEP-380135 and its Metabolites

    Time frame: Up to Day 11

  2. Area Under the Curve from Time Zero to Last Measurable Concentration (AUC0-t) of SEP-380135 and its Metabolites

    Time frame: Up to Day 11

  3. Area Under the Curve from Time Zero to Infinity (AUCinfinity) of SEP-380135 and its Metabolites

    Time frame: Up to Day 11

  4. Time to Maximum Concentration (Tmax) of SEP-380135 and its Metabolites

    Time frame: Up to Day 11

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 2 months

  2. Number of Participants With Potentially Clinically Significant Changes in Vital Signs

    Time frame: Up to 2 months

  3. Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    Time frame: Up to 2 months

  4. Number of Participants With Potentially Clinically Significant Changes in Physical Examinations

    Time frame: Up to 2 months

  5. Number of Participants With Potentially Clinically Significant Changes in Neurological Examinations

    Time frame: Up to 2 months

  6. Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters

    Time frame: Up to 2 months

  7. Number of Participants With Incidence of Suicidal Behavior, Suicidal Ideation and Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 2 months

07

Study locations

1 site
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2025, 1 month.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Dec 26, 2025
StartActual
Mar 7, 2025
Primary completionActual
May 3, 2025
CompletionActual
May 3, 2025
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305779
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Mar 7, 2025
Primary completion
May 3, 2025
Completion
May 3, 2025
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion